Cooley LLP’s Post

a new macrocycle and covalent KRAS G12C inhibitor. From the abstract ...We leveraged structure-based drug design to identify a macrocyclic core structure, and hypothesis-driven optimization of biopharmaceutical properties to further improve metabolic stability and tolerability. https://lnkd.in/dc_UgND9

STARTING SOON: Learn about Soligenix (NASDAQ: SNGX) in today's webinar. $SNGX is a biopharmaceutical company that focuses on orphan diseases with multiple late-stage clinical assets, one with a successful Phase 3 data readout. REGISTER HERE: https://ow.ly/BVoS50S0VC4

Taking biologics manufacturing to commercial scale is a complex–yet exciting–journey as you are nearing market and patients in need. How do you minimize risk and maximize efficiency to be ready for success? Watch this on-demand webinar to learn how R-Pharm leverages our CDMO partnership to help accelerate market readiness. https://lnkd.in/gaHnF3zq

Another successful project in the books ✅ This time we're sharing the outcome of our work with Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company in need of a refresh for its #NewHavenCT office. Check out how it all turned out! 👇 #buildwithcatalyst

In case you missed it! Following the addition of StemSight - Vision Unlimited to our family of licensees earlier this year, our CEO, John E. Milad, and StemSight’s CCO, Ross Macdonald, discuss how #CRISPRCas9 has become a transformative tool in life sciences. If you haven’t already, read our latest article in European Biopharmaceutical Review (EBR): https://shorturl.at/0dgFD

Ligand’s Captisol technology platform has helped optimize the solubility and stability of drugs for some of the world’s leading biopharmaceutical companies including Merck Pfizer Amgen and Gilead Sciences. Today there are more than 15 Captisol-enabled™ products approved worldwide. The leaders of our Captisol team, Drs. Vince Antle and James Pipkin, recently sat down with Lawrence Business Magazine to discuss how this unique technology has changed how drugs are developed and formulated. Read the article here: https://bit.ly/4bRjJtv

Genetic testing can be so beneficial to improving health... For individuals, for families and for entire communities. But like many things in life, a lack of understanding and familiarity with how genetics works greatly hinders it's use in clinical practice. With a robust sponsored-genetic testing program, both #patients and #healthcareproviders work with a #geneticcounselor to understand the test results and map a more-informed path forward to manage the patient's health. In less than 60 seconds, learn how one #biopharma organization did just that to increase patient/provider engagement.

US companies are leading the race for next-generation therapeutics (NGT) championship. However, Europe is catching up. In the infographic, we depicted a pipeline analysis of the biggest pharmaceutical companies in the world. R&D intensity is the R&D expenditure as share of the total revenue. The bubble size represents the NGTs in relation to all entities in the pipeline. Find out more about the approach for mastering next-generation therapeutics in the Porsche Consulting Strategy Paper “Pharma’s transformation towards next-generation therapeutics”: https://lnkd.in/eeUTebZq #Pharma #NGT #NextGenerationTherapeutics #CellAndGeneTherapy #advancedtherapymedicinalproducts

📣NEW! Biopharmaceutical company Rezolute announces the initiation of sunRIZE, a pivotal Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism. Visit https://bit.ly/rezolute3 to learn more about this development! #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease

Biopharmaceutical impurities such as host cell proteins can delay biologics development and production. These elements can have immunogenic effects in patients, forcing scientists to restart process development. Thus, detecting and removing biopharmaceutical impurities is necessary for maintaining drug efficacy and ensuring patient safety. In this webinar brought to you by Cytiva, Andrew Hamilton and Joe Hirano will discuss how to identify, detect, and measure impurities in biologics manufacturing. Register here #AD: https://ow.ly/4HFr50QCgQl